Liftstream is an executive search recruitment company in the life sciences sector
Rare Disease Biotech Summit plc Appoints Erik Ostrowski as CFO
Authored by James Sheppard
Prosensa, Sarepta, PTC, Summit and DART all contribute to the ubiquity of news in Duchenne
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Amsterdam Biotech, Ataluren, Charity, clinical, DART Therapeutics, DMD, Drisapersen, Duchenne Muscular Dystrophy, Eteplirsen, FDA, Gene Williams, Glynn Edwards, GSK, GSK/Prosensa, HT-100, IPO, Market Access, NASDAQ, Netherlands, Orphan drugs, Oxford Biotech, phase II studies, Priority Review, Prosensa, PTC Therapeutics, Rare Disease, regulatory affairs, research and development, Sarepta Therapeutics, Save our Sons, SMT C1100, Summit plc, UK, USA, Utrophin, utrophin modulation
2 Comments